Liraglutide, a Long-Acting Human Glucagon-Like Peptide-1 Analog, Given as Monotherapy Significantly Improves Glycemic Control and Lowers Body Weight Without Risk of Hypoglycemia in Patients With Type 2 Diabetes

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Diabetes Care

Topics

Medicine

Internal Medicine

Endocrinology

Endocrinology, Diabetes And Metabolism

Molecular Biology

Show all topics

DOI

10.2337/dc06-2593